Telaprevir: a new hope in the treatment of chronic hepatitis C?

Advances in Therapy
Andrew J Fowell, Kathryn L Nash

Abstract

More than 180 million people worldwide have chronic hepatitis C (CHC) virus infection, a major cause of liver cirrhosis and its life-threatening complications including liver failure, portal hypertension, and hepatocellular carcinoma. With the current standard of care of pegylated interferon-alpha and ribavirin (PEG-IFN-alpha/RBV), the chances of sustained viral clearance or "cure" are only 40%-50% for genotype 1 infection, which is the most common genotype in western populations. Consequently, there has been a drive to develop new agents specifically targeting essential components of the viral life cycle, such as the hepatitis C virus (HCV) NS3/4A serine protease. Perhaps the most advanced HCV protease inhibitor in clinical development is telaprevir, which has been shown to improve treatment outcomes when combined with PEG-IFN-alpha/RBV in genotype 1 infection, and is currently undergoing phase 3 study. In this review, we summarize the pharmacology, pharmacokinetics, and results of phase 1 and 2 clinical trials of telaprevir, and discuss the likely role of this agent in the future management of CHC.

References

Oct 2, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·D T LauJ H Hoofnagle
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Aug 27, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Gary L DavisJanice Albrecht
Feb 28, 2004·Expert Reviews in Molecular Medicine·Mónica Anzola, Juan José Burgos
Mar 5, 2004·Annals of Internal Medicine·Stephanos J HadziyannisUNKNOWN PEGASYS International Study Group
Oct 28, 2004·Gastroenterology·Giovanna FattovichFrancesco Donato
Feb 16, 2005·Proceedings of the National Academy of Sciences of the United States of America·Kui LiStanley M Lemon
Jul 19, 2005·Clinics in Liver Disease·David L Thomas, Leonard B Seeff
Aug 19, 2005·Nature·Brett D Lindenbach, Charles M Rice
Sep 9, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Peter SimmondsAnders Widell
Aug 8, 2006·Gastroenterology·Hari S ConjeevaramUNKNOWN Virahep-C Study Group
Aug 8, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Tara L KiefferStefan Zeuzem
Sep 20, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Nicole ForestierStefan Zeuzem
May 13, 2008·Gastroenterology·Sharif B MissihaE Jenny Heathcote
Jul 3, 2008·Gastroenterology·Sarah MaylinPatrick Marcellin
Aug 19, 2008·Journal of Hepatology·Teresa SantantonioJ Tilman Gerlach
Mar 31, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marc G GhanyUNKNOWN American Association for the Study of Liver Diseases
May 1, 2009·The New England Journal of Medicine·John G McHutchisonUNKNOWN PROVE1 Study Team
May 1, 2009·The New England Journal of Medicine·Christophe HézodeUNKNOWN PROVE2 Study Team
Aug 12, 2009·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Sarah L Fishman, Andrea D Branch
Apr 9, 2010·The New England Journal of Medicine·John G McHutchisonUNKNOWN PROVE3 Study Team

❮ Previous
Next ❯

Citations

Nov 3, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H L ZaaijerG Frijstein
Jan 12, 2011·Current HIV/AIDS Reports·Eva A Operskalski, Andrea Kovacs
Jan 4, 2012·British Journal of Anaesthesia·C J E Watson, J H Dark
Nov 30, 2011·The Journal of Infectious Diseases·Hidenori OchiKazuaki Chayama
Jan 20, 2012·The Journal of Antimicrobial Chemotherapy·Nigel J HorscroftHelen Bright
May 31, 2011·Pharmacology & Therapeutics·Zoe RaglowYu-Jui Yvonne Wan
Nov 26, 2010·Trends in Molecular Medicine·Michael A Gelman, Jeffrey S Glenn
Feb 15, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Maria StepanovaZobair M Younossi
Jun 17, 2014·Journal of Viral Hepatitis·S AkamatsuUNKNOWN Hiroshima Liver Study Group
May 12, 2011·The Annals of Pharmacotherapy·Lisa S SmithJoanna Woten
Jan 17, 2019·Toxicological Sciences : an Official Journal of the Society of Toxicology·Khetam Ali AlhilaliDean J Naisbitt
May 30, 2012·Nature Reviews. Gastroenterology & Hepatology·C Nelson HayesKazuaki Chayama
Sep 10, 2013·Alimentary Pharmacology & Therapeutics·K ZachouL Muratori
Nov 10, 2013·Physics in Medicine and Biology·Gregory SmythJames L Bedford

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.